Trials / Unknown
UnknownNCT05100329
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer
Safety, Tolerability, and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer: A Multicenter, Open-label, Phase Ⅱ Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mitoxantrone hydrochloride liposome injection in patients with advanced pancreatic cancer.
Detailed description
This is a multicenter, open-label, phase Ⅱ study aimed to evaluate the safety, tolerability, and efficacy of mitoxantrone hydrochloride liposome injection in patients with advanced pancreatic cancer. Patients enrolled in this study will receive mitoxantrone hydrochloride liposome injection every 3 weeks (q3w, a cycle) until disease progression, intolerable toxicity, death, or withdrawal by investigator or patient decision (a maximum of 8 cycles).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitoxantrone Hydrochloride Liposome injection | 20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle) |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2023-11-01
- Completion
- 2024-05-01
- First posted
- 2021-10-29
- Last updated
- 2021-10-29
Source: ClinicalTrials.gov record NCT05100329. Inclusion in this directory is not an endorsement.